Duvyzat
(Givinostat)Phase 3Small molecule
ItalfarmacoDuvyzat is a small molecule that works as a HDAC Inhibitor.[2] It is being investigated across 5 indications, with its most advanced program in Phase 3.[1]
Duvyzat is one of 137 small molecule programs targeting Polycythemia Vera. It is currently in Phase 3.
5
Indications
15
Total Trials
5
Active Trials
136
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
5
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
125 competitors in Duchenne Muscular Dystrophy
#DrugCompanyPhaseTrials
1Cialis
Eli LillyPhase 3
Nolvadex
AstraZenecaPhase 3
Aldactone
PfizerPhase 3
Rifadin
SanofiPhase 3
Avicel
SSanthera Pharmaceuticals
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Duvyzat
ItalfarmacoPhase 3
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Bystolic
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Creatine Monohydrate
MMassachusetts General Hospital
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Polycythemia Vera3 trials
Tics2 trials
Duchenne Muscular Dystrophy2 trials
Juvenile Idiopathic Arthritis2 trials
5 more indications
TIA1 trial
Muscular Dystrophy1 trial
Becker muscular dystrophy1 trial
Regulatory
FDA Approval Timeline[4]
Mar 21, 2024
DUVYZAT
NDA NDA217865
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Givinostat. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]
- [7]